Navigation Links
Lupin Announces Launch of Generic Levaquin® Tablets
Date:6/22/2011

BALTIMORE, June 22, 2011 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Ortho McNeil's Levaquin® (levofloxacin) tablets.  Commercial shipment of the product has commenced.

Lupin's levofloxacin 250 mg, 500 mg and 750 mg tablets are the AB-rated generic equivalent of Levaquin, a synthetic broad spectrum antibacterial agent used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.   Levaquin tablets had annual sales of approximately $1.6 billion for the twelve months ended March 2011, based on IMS Health sales data.

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The Company today has significant market share in Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition holding global leadership positions in the Anti-TB and Cephalosporins space.  

Today, Lupin is the 5th largest and fastest growing Top 5 generics player in the US (by prescriptions), the only Asian company to achieve that distinction.   The company is also the fastest growing top 10 pharmaceutical players in India, Japan and South Africa. (IMS)

For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 million and Rs. 8,626 million respectively.  Please visit http://www.lupinworld.com for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited.  Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release

*Levaquin® is a registered trademark of Ortho McNeil Pharmaceuticals, Inc.

For More Information:
Contact: Edith St-Hilaire
Director of Marketing
(410) 576-2000


'/>"/>
SOURCE Lupin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer
2. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
3. Lupin Expands Branded Play
4. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
5. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
6. Oxford BioMedica Announces Ocular Programme Update
7. China Medical Technologies Announces Strategic Collaboration Between its Subsidiary, GP Medical, and Da An Health
8. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
9. Molnlycke Health Care U.S. Announces Senior Management Changes
10. Next-Generation Pharmacist™ Awards Program Announces 2011 Finalists
11. Robbins & Myers Announces Regular Quarterly Cash Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DURHAM, N.C. , Feb. 8, 2016  Avista ... appointed Eric Setzer as Chief Financial Officer (CFO). ... over twenty years of experience in various roles within ... Avista Pharma, he served as the Executive Director of ... organization in Raleigh, NC . Previously, ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... 2016 Palatin Technologies, Inc. (NYSE MKT: ... therapeutics for the treatment of diseases with significant ... that the United States Patent and Trademark Office ... U.S. Patent Application Serial Number 14/313,258 (the ,258 ... treating female sexual dysfunction using the formulation and ...
Breaking Medicine Technology:
(Date:2/8/2016)... Encinitas, CA (PRWEB) , ... February 08, 2016 ... ... study showing greater than 50% lower incidence rate of type 2 diabetes in ... national averages. ”It is time to make a change in public health,” states ...
(Date:2/8/2016)... , ... February 08, 2016 , ... TopConsumerReviews.com recently awarded ... Mole removal products. , Moles are derived from a cluster of melanin when exposed ... the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering ... 2016 in honor of his birthday on February 10th. During this time, people ... is known by over 250,000 people from over 40 different countries as an “ordinary ...
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
Breaking Medicine News(10 mins):